Browse Illinois Research and Scholarship by Author "Sherkow, Jacob S."

  • Zettler, Patricia J.; Sherkow, Jacob S.; Greely, Henry T. (JAMA Internal Medicine, 2014-03-01)
    On November 22, 2013, the US Food and Drug Administration (FDA) effectively halted health-related direct-to-consumer genetic testing in the United States by sending a warning letter to 23andMe, the leading company in the ...

    application/pdf

    application/pdfPDF (51kB)
  • Sherkow, Jacob S. (University of Washington Law Review, 2015-04-13)
    Recent patent litigation reform efforts have focused on every branch of government — Congress, the President, and the federal courts — save the fourth: administrative agencies. Agencies, however, possess a variety of ...

    application/pdf

    application/pdfPDF (995kB)
  • Sherkow, Jacob S.; Minssen, Timo (Edward Elgar Publishing, 2020-08-19)
    Whether the E.U. Trade Secrets Directive sufficiently and appropriately covers cutting-edge complex technologies is of critical interest to policy-makers, scientists, and commercial developers alike. One such technology — ...

    application/pdf

    application/pdfPDF (361kB)
  • Sherkow, Jacob S. (Yale Law Journal, 2013-04-01)
    The Mayo Court's novel test for patent eligibility — whether or not an invention involves “well-understood, routine, conventional activity, previously engaged in by researchers in the field” — focuses on how an invention ...

    application/pdf

    application/pdfPDF (97kB)
  • Trück, Johannes; Eugster, Anne; Barennes, Pierre; Tipton, Christopher M.; Luning Prak, Eline T.; Bagnara, Davide; Soto, Cinque; Sherkow, Jacob S.; Payne, Aimee S.; Lefranc, Marie-Paule; Farmer, Andrew; The AIRR Community; Bostick, Magnolia; Mariotti-Ferrandiz, Encarnita (eLife Sciences Publications, 2021-05-26)
    Use of adaptive immune receptor repertoire sequencing (AIRR-seq) has become widespread, providing new insights into the immune system with potential broad clinical and diagnostic applications. However, like many high-throughput ...

    application/pdf

    application/pdfPDF (963kB)
  • Sherkow, Jacob S. (Northwestern University Law Review, 2017-12-20)
    This contribution to the Northwestern University Law Review's Bridge II micro-symposium discusses collaborations between the law and STEM fields and real-world examples of where such collaborations have gone well--and ...

    application/pdf

    application/pdfPDF (114kB)
  • Sherkow, Jacob S. (Michigan Law Review, 2008-12-03)
    In Indianapolis v. Chase National Bank, 1941, the Supreme Court established the doctrine of realignment, requiring federal courts to examine the issues in dispute and realign each party as plaintiff or defendant if necessary. ...

    application/pdf

    application/pdfPDF (269kB)
  • Sherkow, Jacob S. (University of North Carolina School of Law, 2018-01-17)
    The state of publicly funded science is in peril. Instead, new biomedical research efforts — in particular, the recent funding of a “Cancer Moonshot” — have focused on employing public-private partnerships, joint ventures ...

    application/pdf

    application/pdfPDF (624kB)
  • Rai, Arti K.; Sherkow, Jacob S. (Nature Biotechnology, 2016-03-10)
    What have we learned from 20 tumultuous years of patent law in the life sciences? Is patenting likely to be as important for the industry in the future?

    application/pdf

    application/pdfPDF (729kB)
  • Sherkow, Jacob S. (The CRISPR Journal, 2019-10-09)
    Since its advent in 2012, CRISPR has spawned a cottage industry of bioethics literature. One principal criticism of the technology is its virtually instant widespread adoption prior to deliberative bodies conducting a ...

    application/pdf

    application/pdfPDF (151kB)
  • Sherkow, Jacob S. (The CRISPR Journal, 2018-02-01)
    The development of CRISPR depends, in part, on the patents—past, present, and future—covering it. As for the past, the origins of the CRISPR patent landscape predate its use as a gene editing technology. Fundamental pat- ...

    application/pdf

    application/pdfPDF (359kB)
  • Sherkow, Jacob S. (Yale Journal of Biology & Medicine, 2017-12-17)
    Patent issues surrounding CRISPR, the revolutionary genetic editing technology, may have important implications for the public health. Patents maintain high prices for novel therapies, limiting patient access. Relatedly, ...

    application/pdf

    application/pdfPDF (475kB)
  • Contreras, Jorge L.; Sherkow, Jacob S. (Science, 2017-02-17)
    Several research institutions are embroiled in a legal dispute over the foundational patent rights to CRISPR-Cas9 gene-editing technology, and it may take years for their competing claims to be resolved. But even before ...

    application/pdf

    application/pdfPDF (288kB)
  • Sherkow, Jacob S. (The CRISPR Journal, 2018-10-23)
    An appellate court in the United States affirmed the Patent Office's finding that the Broad Institute's patents covering eukaryotic applications of CRISPR-Cas9 was separately patentable over the University of California's ...

    application/pdf

    application/pdfPDF (121kB)
  • Sherkow, Jacob S. (Duke University Law Journal, 2016-03-23)
    Profs. Allison and Ouellette’s Article, How Courts Adjudicate Patent Definiteness and Disclosure, 65 Duke L.J. 609 (2015), on courts’ adjudication of certain patent disputes presents some surprising data: pharmaceutical ...

    application/pdf

    application/pdfPDF (139kB)
  • Crevel, Gilles; Hashimoto, Reina; Vass, Sharron; Sherkow, Jacob S.; Yamaguchi, Masamitsu; Heck, Margarete M.S.; Cotterill, Sue (PLoS One, 2007-09-05)
    The MCM2-7 proteins are crucial components of the pre replication complex (preRC) in eukaryotes. Since they are significantly more abundant than other preRC components, we were interested in determining whether the entire ...

    application/pdf

    application/pdfPDF (396kB)
  • Sherkow, Jacob S.; Zettler, Patricia J. (New York University School of Law, 2021-08-20)
    Drug pricing disputes, while significant public health concerns, are not typically immediate life or death matters. But they may be for certain emergency medicines, medicines used for potentially lethal and rapidly onset ...

    application/pdf

    application/pdfPDF (337kB)
  • Sherkow, Jacob S.; Aboy, Mateo (Nature Portfolio, 2020-09-04)
    The interaction between patents and FDA’s De Novo and 510(k) regulatory pathways has the potential to threaten follow-on innovation for medical devices.

    application/pdf

    application/pdfPDF (744kB)
  • Sherkow, Jacob S. (Nature Biotechnology, 2013-04-05)
    An imminent US Supreme Court ruling should resolve one of the thorniest legal issues facing pharmaceutical companies today.

    application/pdf

    application/pdfPDF (140kB)
  • Guerrini, Christi; Sherkow, Jacob S.; Zettler, Patricia J. (Cambridge University Press, 2021-08-01)
    “Biohacking” has emerged as a cultural and scientific phenomenon. Although there is no consensus on the precise definition of “biohacking,” the term generally describes biological investigations and interventions that are ...

    application/pdf

    application/pdfPDF (133kB)